Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...
An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer (NSCLC) ...
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...
Foundation grants $3.55 million in new research awards, bringing annual total funding awarded to $3.87 million ...
News Medical on MSN4d
Multi-omic profiling sheds light on chemo-immunotherapy resistance in lung cancerThe study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and ...
A new molecular imaging agent can accurately identify a crucial biomarker found among many different types of cancer ...
Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that ...
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...
Fibroblastic reticular cells (FRCs) create T-cell-supportive niches within lung cancer tumors, facilitating T-cell migration, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback